R.
Kerdjoudj
a,
M.
Pniok
b,
C.
Alliot
cd,
V.
Kubíček
b,
J.
Havlíčková
b,
F.
Rösch
e,
P.
Hermann
*b and
S.
Huclier-Markai
*ac
aLaboratoire Subatech, UMR 6457, Ecole des Mines de Nantes/CNRS/IN2P3/Université de Nantes, 4 Rue A. Kastler, BP 20722, F-44307 Nantes Cedex 3, France. E-mail: sandrine.huclier@subatech.in2p3.fr; Fax: +33-251858452; Tel: +33-251858537
bDepartment of Inorganic Chemistry, Faculty of Science, Universita Karlova, Hlavova 2030, CZ-12843 Prague 2, Czech Republic. E-mail: petrh@natur.cuni.cz; Fax: +420-221951253; Tel: +420-221951263
cARRONAX GIP, 1 rue Arronax, F-44817 Nantes Cedex, France
dCRCNA, Inserm/CNRS/Université de Nantes, 8 quai Moncousu, 44007 Nantes Cedex 1, France
eInstitute of Nuclear Chemistry, Johannes-Gutenberg-University of Mainz, Fritz-Strassmann-Weg 2, D-55128 Mainz, Germany
First published on 30th November 2015
The complexation ability of DOTA analogs bearing one methylenephosphonic (DO3AP) or methylenephosphinic (DO3APPrA and DO3APABn) acid pendant arm toward scandium was evaluated. Stability constants of their scandium(III) complexes were determined by potentiometry combined with 45Sc NMR spectroscopy. The stability constants of the monophosphinate analogues are somewhat lower than that of the Sc–DOTA complex. The phosphorus acid moiety interacts with trivalent scandium even in very acidic solutions forming out-of-cage complexes; the strong affinity of the phosphonate group to Sc(III) precludes stability constant determination of the Sc–DO3AP complex. These results were compared with those obtained by the free-ion selective radiotracer extraction (FISRE) method which is suitable for trace concentrations. FISRE underestimated the stability constants but their relative order was preserved. Nonetheless, as this method is experimentally simple, it is suitable for a quick relative comparison of stability constant values under trace concentrations. Radiolabelling of the ligands with 44Sc was performed using the radioisotope from two sources, a 44Ti/44Sc generator and 44mSc/44Sc from a cyclotron. The best radiolabelling conditions for the ligands were pH = 4, 70 °C and 20 min which were, however, not superior to those of the parent DOTA. Nonetheless, in vitro behaviour of the Sc(III) complexes in the presence of hydroxyapatite and rat serum showed sufficient stability of 44Sc complexes of these ligands for in vivo applications. PET images and ex vivo biodistribution of the 44Sc–DO3AP complex performed on healthy Wistar male rats showed no specific bone uptake and rapid clearance through urine.
Among the radionuclides available, there is significant interest in the therapeutic radioisotope 47Sc (β−, τ1/2 3.35 d, Eβ 0.143 (68%) and 0.204 MeV (32%); γ, Eγ 159.4 keV, 68%) as it matches with the positron-emitting 44Sc (β+, τ1/2 3.97 h, Eβ 0.63 MeV, 94.3%) or 43Sc (β+, τ1/2 3.89 h, Eβ 0.344 MeV (17.2%) and 0.508 MeV (70.9%)) and, thus, they form an ideal theranostic pair. The potential of 47Sc for nuclear medicine has been already investigated.2–4 The possibility of 47Sc production by neutron irradiation of 47Ti and consecutive solid-phase extraction chromatography has been evaluated.5 Very recently, the feasibility of photonuclear production of 47Sc from 48Ca or 47Ca/47Sc generators has been studied.5,6 Due to its dominant positron emission, 44Sc is very suitable for PET imaging. Its half-life perfectly matches the pharmacokinetics of small molecules or (oligo)peptides. In addition to two collinear γ rays produced by annihilation, 44Sc offers a third γ ray suitable for three-photon coincidence imaging which may further increase resolution of the current PET imaging.7 In addition, the radioisotope can be produced together with its long-lived isomeric excited nucleus, 44mSc (γ, τ1/2 2.44 d, 98.8%, Eγ 270.9 keV), decaying to 44Sc with soft γ emission. The half-life of 44mSc matches the in vivo pharmacokinetics of antibodies and, due to its low-energy transition (recoil energy only 0.89 eV), it can serve as an in vivo generator of 44Sc as the daughter 44Sc stays inside the chelator after the decay of the parent 44mSc nucleus.8 The 44mSc/47Sc theranostic pair with both radionuclides having similar half-lives is very suitable for radiopharmaceuticals utilizing antibodies or their fragments and, thus, they form a unique and very promising theranostic pair for cancer treatments. Utilizations of the Sc-based theranostic pairs can be spread from antibody radioimmunotherapy (the 44mSc/47Sc pair) to treatments with labeled oligopeptides or small molecules (the 44Sc/47Sc pair).
44Sc can be produced by a generator employing 44Ti as a long-lived parent radioisotope.9,10 The radioisotope can be also produced in most medical cyclotrons designed for 18F production.11 The ARRONAX cyclotron produces the 44mSc/44Sc pair from an enriched 44CaCO3 target via the deuteron production route12 which seems to be a promising route to obtain non-carrier-added (NCA) 44Sc with an optimized 44mSc/44Sc ratio. Other production routes allow a better 44mSc/44Sc ratio by bombarding a 45Sc target13–15 leading to a carrier-added product and it is a major drawback for the production of radiopharmaceuticals.
Metallic radioisotopes utilized in nuclear medicine must be tightly bound in a complex to avoid non-specific deposition in tissues. These complexes must exhibit a high thermodynamic stability, a high selectivity for a particular metal ion, a fast complexation of the metallic radioisotopes, kinetic inertness as well as an ability to be conjugated to a biological vector molecule (bifunctional ligands). The design of new radiopharmaceuticals is a viable multidisciplinary field involving physics, chemistry, biology and medicine.16–22
Scandium is a cousin of lanthanides but with some differences. Sc(III) is smaller than Ln(III) (thus, being harder and with a higher preference for hard oxygen donor ligands) and it prefers donor numbers from six to eight. However, the chemistry of trivalent scandium is much less developed than that of trivalent lanthanides.23 Mostly, multidentate ligands already used in Gd(III)-based MRI contrast agents as well as for radiolanthanides, i.e. derivatives of DTPA (DTPA = diethylenetriamine-N,N,N′,N′′,N′′-pentaacetic acid) or DOTA (DOTA = 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid), are the first choice to bind the ion. It has been shown that DOTA derivatives are suitable ligands for scandium radioisotopes.24 Their oligopeptide,10,25–29 antibody30,31 or other32,33 conjugates have been investigated for complexation of the scandium radionuclides.
Recently, we have investigated the chemistry of Sc(III)–DTPA and Sc(III)–DOTA complexes in detail.34 The study confirms that DOTA is a very suitable chelator for trivalent scandium. Efficient radiolabeling of DOTA with 44m/44Sc requires elevated temperatures (>70 °C).8 For oligopeptides, such a high temperature is not a critical parameter. However, antibodies or their fragments need a much lower labelling temperature (mostly below 37 °C) to preserve their immunoreactivity. Slow formation kinetics of DOTA-like chelators remains an important obstacle limiting their use in some radiopharmaceuticals. Therefore, ligands permitting formation of complexes at much lower temperatures to label antibody conjugates are sought.
Scandium(III) is a “harder” metal ion than trivalent lanthanides and oxygen atoms in derivatives of phosphoric acid have a “harder” character than those in the carboxylate group. Thus, phosphonic (R–PO3H2) or phosphinic (R2PO2H) acid pendants may alter ligand behaviour in the desired direction.35 Such DOTA derivatives form thermodynamically stable and kinetically inert complexes with somewhat enhanced complexation kinetics.36–38 Their complexes/conjugates are stable in vivo and show good pharmacokinetic properties due to their high hydrophilicity.39–41 Trivalent gallium is a similar very hard metal ion and phosphinic acid derivatives of NOTA (NOTA = 1,4,7-triazacyclononane-1,4,7-triacetic acid) showed much faster labeling with 68Ga as compared to the parent ligand.42,43
Therefore, monophosphorus acid DOTA analogs, DO3AP, DO3APABn and DO3APPrA (Fig. 1) were considered as better ligands than DOTA. Solution investigations of their complexes were complemented by radiochemical studies with non-carrier-added (NCA) 44Sc from two sources, a 44Ti/44Sc generator and from an ARRONAX cyclotron, and by in vivo/in vitro evaluation of the radiolabelled complexes.
Samples for NMR titrations were prepared similarly to the out-of-cell titration as given above and analogously to the previous paper.34 Stock solutions of the ligands, ScCl3, HCl, KCl (if necessary), and water were mixed into tubes (final cL = 0.004 M, L:
Sc molar ratio 1
:
0.95, V0 = 1 mL; I = 0.1 M (H,K)Cl, with no control of the ionic strength at pH < 1.1) to obtain pH in the range 0.5–1.3 and the tubes were tightly closed (12–15 titration points); the equilibration time was seven days at room temperature. Species abundance in each tube (i.e. the titration point) was determined by 45Sc NMR measurements. Two parallel titrations were carried out. To determine the equilibration time, other samples were prepared as above at three pHs, the samples were left at room temperature and 45Sc NMR spectral changes with time were followed.
Samples for equilibrium studies with the Sc(III)–DO3AP system were prepared by mixing stock solutions of DO3AP, ScCl3, 17% or 5% aq. HCl, 1.1 M or 0.2 M HCl, 0.2 M KCl (if necessary), and water into tubes (conditions as above). The solutions were left to equilibrate for at least seven days at room temperature and pH values were determined as above. Job's method was employed to determine stoichiometry of the out-of-cage species in the Sc(III)–DO3AP system. Each sample was prepared in a vial by mixing 0.1 M aq. ScCl3 and 0.1 M aq. DO3AP stock solutions with 1 M aq. HCl (final volume 1 mL, pH 0.22, cSc = 4–20 mM, cSc+L = 40 mM, 7 points, equilibration time seven days). To determine protonation constants of [Sc(DO3AP)]2− isomeric species, a pre-prepared complex was dissolved in H2O in a 10 mm NMR tube and the desired pH was adjusted with aq. HCl or aq. (NMe4)OH (cScL ∼ 0.01 M, pH range 4.15–7.67, 26 points). The pH was determined by a freshly calibrated (three buffers) combined pH electrode fitting the NMR tube.
To characterize the [Sc(DO3APPrA)]2−, [Sc(DO3APABn)]− and [Sc(DO3AP)]2− complexes, their solutions were prepared by dissolving the appropriate ligand (0.05 mmol), ScCl3·6H2O (0.055 mmol) in water (1 mL) and adjusting the solution pH to ∼7 with solid Li2CO3. Then, the solutions were stirred in sealed vials at 90 °C for 2 h. Excess of Sc(III) precipitated as white Sc(III)–carbonate/hydroxide and was filtered off with a syringe filter and the filtrate was evaporated to dryness. The solid was dissolved in D2O (0.5 mL) to obtain a solution with the complex concentration ∼0.1 M.
The resulting suspension was equilibrated for 24 h and the pH was re-adjusted, if necessary. In preliminary experiments, the sufficient equilibration time was found to be six days for all the systems. Solid and liquid phases were separated by sedimentation. Aliquots (1 mL) of the supernatant were taken for ICP-AES analysis. Scandium concentrations were determined and experimental Kd values were plotted as a function of the total ligand concentration in the solutions. These dependences were used for stability constant determinations. To check the potential presence of protonated complexes, other sets of experiments were performed at fixed ligand concentrations (10−3 M) in the pH range 2–7 utilizing the same protocol as described above.
Animal studies were carried out in accordance with the guidelines of the French law on Animal Studies. Biodistribution of the 44Sc–DO3AP complex was followed in four healthy Wistar rats injected intravenously with 44Sc–DO3AP solution (100 μL, 1 MBq). The animals were imaged at selected time intervals, then sacrificed and dissected. The rats were sacrificed at 30 min and 1 h, two rats per time point. Organs were collected, weighed, counted on a gamma counter, and the percentage of injected dose per gram of tissue (% ID per g) was calculated. PET images were acquired using a Siemens Inveon micro PET/CT instrument.
![]() | ||
Fig. 2 45Sc and 31P{1H} NMR spectra of [Sc(DO3AP)]2− (A), [Sc(DO3APPrA)]2− (B) and [Sc(DO3APABn)]− (C) in D2O (0.1 M, pD = 7.1). |
The 45Sc NMR spectra (Fig. 2) recorded in 0.1 M solutions of pre-prepared complexes showed very broad peaks 87 ppm (ϖ1/2 ∼ 5200 Hz), 87 ppm (ϖ1/2 ∼ 5700 Hz) and 90 ppm (ϖ1/2 ∼ 7200 Hz) for the [Sc(DO3AP)]2−, [Sc(DO3APPrA)]2− and [Sc(DO3APABn)]− complexes, respectively. The values are similar to those observed for [Sc(DOTA)]− (δSc ∼ 100 ppm, ϖ1/2 ∼ 4300 Hz)34 also confirming the formation of the in-cage complex for all ligands.
The behaviour of the Sc(III)–DO3AP system was analogous to that observed for the Sc(III)–DO3APABn and –DO3APPrA systems only at pH above ∼3.8; no 45Sc and two 31P{1H} NMR peaks were observed confirming the formation of the in-cage complex (Fig. 3). From potentiometric titrations in this pH range, only the constant corresponding to protonation of the coordinated phosphonate group in the in-cage complex, logKa 5.29, could be determined (Table S2†). However, unexpected results were obtained for the Sc(III)–DO3AP system in more acidic solutions. Here, other peaks appeared in both NMR spectra: δSc ∼ 23 ppm, and δP −8.3 ppm (Fig. 3). The 45Sc NMR signal of the Sc(III)-aqua complex starts to be observable below pH ∼ 0.8. Surprisingly, the signal at δSc ∼ 23 ppm was present even in extremely acidic solutions (up to 1
:
1 aq. HCl). Most probably, the NMR signal can be assigned to an out-of-cage complex species where at least the protonated phosphonate group (and, possibly, the acetate group(s) as well) is bound to the scandium(III) ion. Such a coordination mode of the phosphonate group has been observed with metal ions (e.g. trivalent lanthanides) even under highly acidic conditions.51,52 The overall stoichiometry of the Sc(III)–DO3AP species present in the acidic solutions can be roughly estimated as Sc
:
L = 1
:
2 from a Job-like plot of NMR signal intensities (Fig. S3†) and, overall, the speciation is rather complicated. Unfortunately, such solution behaviour (i.e. not determinable correct Sc/DO3AP stoichiometry as well as the number of protons in the species) precluded determination of the Sc(III)–DO3AP complex stability constants as the system is too complex to be modeled by equilibrium constant calculations.
![]() | ||
Fig. 3 45Sc (A) and 31P{1H} (B) NMR spectra of equilibrated solutions prepared by mixing ScCl3 and DO3AP (cSc = cL = 0.004 M). The given pH values are those of the equilibrated solutions. |
The stability constants were determined by a combination of three techniques, 45Sc NMR, out-of-cell and direct (in-cell) potentiometry (for more detailed discussion, see the ESI†). The stability constants are presented in Table 1 and the experimentally determined overall stability constants are given in Table S2.† The corresponding distribution diagrams are shown in Fig. 4. The Sc(III) complexes of DO3APABn and DO3APPrA are more stable than their lanthanide(III) complexes (logKLuL 24.0 and 25.5, respectively)37 but less stable than the [Sc(DOTA)]− complex (log
KScL 30.79).34 The difference in stability constants between the lutetium(III) and scandium(III) complexes is similar for all ligands. The first Sc(III) complex protonation constants, corresponding to the protonation of amino or carboxylate groups in the phosphorus side chain, are almost identical to those of lutetium(III) complexes.37 The next two protons are attached to the ring nitrogen atoms with the formation of out-of-cage complexes where the scandium(III) ion is bound only to pendant arm oxygen atom(s). Such a chemical model has already been suggested for lanthanide(III)–DO3AP systems36 and such out-of-cage species diprotonated on ring amines have been observed for lanthanide(III) complexes in the solid state as well as in solution.41,53 The very high abundance of the triprotonated species (Fig. 4) can be caused by a strong preference of trivalent scandium for hard phosphinate oxygen donors in the out-of-cage species.
![]() | ||
Fig. 4 Distribution diagram for the Sc3+–DO3APABn system (A) and the Sc3+–DO3APPrA system (B). cSc = cL = 0.004 M. The abundance of free Sc3+ ion (□) was determined by 45Sc NMR spectroscopy. |
Equilibriuma | DO3APABn | DO3APPrA![]() |
DO3AP![]() |
DOTA | DTPA |
---|---|---|---|---|---|
a Charges are omitted for clarity.
b The most acidic protonation constants of DO3APPrA were re-determined: log![]() ![]() |
|||||
L + Sc ⇌ [Sc(L)] | 27.03 | 28.31 | 30.79 | 27.43 | |
[Sc(L)] + H ⇌ [Sc(HL)] | 5.17 | 4.18 | 5.29 | 1.0 | 1.36 |
[Sc(HL)] + 2H ⇌ [Sc(H3L)] | 3.96 | 4.35 | |||
[Sc(OH)(L)] + H ⇌ [Sc(L)] + H2O | 12.83 | 12.03 | 12.44 |
As stability constants of the Sc(III)–DO3AP complex cannot be determined by the above method, a competition method with trivalent ytterbium (as the metal ion with a very high stability constant with DO3AP, logKYbL ∼ 28.5)36 as well as transchelation with DTPA were tested. In both cases, the determination failed due to problems with too slow kinetics of the transmetallation or transchelation.
Adsorption of the free Sc3+-aqua ion on imino-diacetate chelating groups can be described by the following equilibrium (eqn (1)):
![]() | (1) |
The overlined species refer to the species present on the resin (adsorbed species). The electroneutrality of each phase is required. Stability constants could be estimated by fitting dependence of the distribution coefficient (Kd) of Sc(III) between the resin and the supernatant on the total ligand concentration in the supernatant. If both the ligand and the exchange resin are used in a large excess in comparison with the initial Sc concentration, Kd values could be expressed as eqn (2):
![]() | (2) |
![]() | (3) |
![]() | (4) |
As αSc(L,OH) is a function of the ligand protonation constants and stability constants of the corresponding Sc(III) complexes, the stability constants could be calculated by fitting of the Kd values determined at various ligand excesses and at various solution pH values according to eqn (2). For the full set of equations and more explicit explanation of the method, see the ESI.†
Transchelation kinetics of macrocyclic ligands is generally slow. Therefore, the equilibration time was at least six days. The experimental data are depicted in Fig. 5 and S5.† To obtain a good fit of the data obtained for various pH values, not only [Sc(L)] but also [Sc(HL)] species had to be included in all systems (for a comparison of different models, see Fig. S5†). The results are summarized in Table 2. The values obtained by the FISRE method are in a reasonable qualitative agreement with the values obtained by potentiometry/NMR (Table 1) if errors naturally accompanying utilization of trace concentrations and very high absolute values of the constants are taken into account.
![]() | ||
Fig. 5 The Sc(III)–ligand isotherms obtained by the FISRE method: DO3AP (full line); DO3APPrA (dashed line) and DO3APABn (dotted line). The lines correspond to the fitting as explained in the ESI.† Solution pH and concentration of the Chelex resin were adjusted for each batch to minimize the global uncertainty of the partition coefficient (I = 0.1 M NaCl). |
The results show that the method can be used for fast screening of complex stabilities as it works with significantly lower amounts of compounds in comparison with common techniques such as potentiometry or NMR. Further, it could also be used for studying “problematic” metal ions (e.g. trivalent or tetravalent metal ions) or ligands. It can be used for a qualitative evaluation of metal ion–ligand interactions at the trace level. In addition, the FISRE method is more easy to carry out, faster and operationally cheaper than the “standard” methods (here, the stability constant of the [Sc(DO3AP)]2– complex cannot be determined by the conventional methods) and gives results which can be used for evaluation of the complexation ability of new ligands toward metal ions intended to be utilized in radiopharmaceuticals.
Radioisotope source | n ligand (nmol) | Ligand | |||
---|---|---|---|---|---|
DOTA | DO3AP | DO3APPrA | DO3APABn | ||
Generator 44Sc | 1 | 10.1 | 10.0 | 8.6 | 1.9 |
3 | 96.5 | 91.6 | 88.5 | 4.3 | |
5 | 96.7 | 93.8 | 95.7 | 20.8 | |
10 | 96.8 | 95.3 | 97.0 | 91.1 | |
20 | 97.3 | 95.7 | 97.1 | 94.7 | |
25 | 97.1 | 96.6 | 96.5 | 95.1 | |
30 | 97.6 | 97.6 | 97.7 | 96.6 | |
Cyclotron 44mSc/44Sc | 0.02 | 31.1 | 36.1 | 28.4 | 32.5 |
0.07 | 97.8 | 97.4 | 88.3 | 90.6 | |
0.12 | 98.9 | 98.8 | 94.2 | 92.7 | |
0.17 | 99.4 | 98.8 | 98.9 | 94.7 | |
0.24 | 99.6 | 99.1 | 99.1 | 96.4 |
As the excess of a chelator over a metal radioisotope determines the accessible specific activity, the influence of the chelator/radioscandium molar ratio on the radiochemical yield was tested under conditions previously successfully used for DOTA derivatives: labelling time 30 min, pH 4 and temperature 70 °C. Results are presented in Table 3. With generator 44Sc, overall radiolabelling yields for 44Sc–DOTA and 44Sc–DO3AP were quite similar ranging from 10% to 95% if 1 or 5 nmol of the ligand, respectively, were added. In contrast, the radiolabeling yield for 44Sc–DO3APABn was much lower (approx. 25% if <10 nmol of DO3APABn was used) and 20 nmol of the ligand was required to reach 95% radiolabeling. With the cyclotron 44m/44Sc, the amount of the ligands required to reach the same radiolabelling yields was significantly lower, although the same general trend was observed. Thus, 0.2 nmol of the ligands is enough for the cyclotron 44m/44Sc to obtain a minimum of 95% radiolabeling versus more than 5 nmol of the ligands for the 44Sc from the 44Ti/44Sc generator. The differences between the radioscandium from the two sources could be explained by the different contents of cold metallic impurities competing with the ligands for the scandium radioisotope.
Specific activity (SA), a measure of the radioactivity per unit mass of the compound, is one of the major criteria for radiopharmaceuticals and should be as high as possible. Specific activities of the radioscandium from each source and for each ligand were calculated and the values are summarized in Table S3.† The calculated specific activity of the cyclotron 44m/44Sc is always higher than 10 MBq nmol−1 (4 h after end of beam). However for the generator 44Sc, the specific activity was estimated to be max. ∼2 MBq nmol−1 (for DOTA; 4 h after the end of elution).
The influence of temperature and solution pH was tested under conditions suggested by the experiments above: 20 nmol and 0.2 nmol of the ligands for the generator 44Sc and the cyclotron 44m/44Sc, respectively, and at a reaction time of 30 min. The results are plotted in Fig. 6. At 40 °C, the generator 44Sc revealed 30% labeling for DO3AP whereas 5–8% yield was achieved for the other ligands. The yields increased with temperature as expected, to more than 90% and 95% at 70 °C and 90 °C, respectively, but with no difference among the ligands. Surprisingly at low temperatures, the labelling yield with DOTA was significantly lower than that with DO3AP. On the other hand with the cyclotron 44m/44Sc, even if concentrations of the ligands were much lower compared to those for the generator 44Sc, higher radiolabeling yields, mainly at lower temperatures, were obtained. At 40 °C (a temperature still suitable for antibody labelling), radiolabelling yields >40% (44Sc–DO3APABn), >55% (44Sc–DO3AP) and ∼70% (44Sc–DOTA) were observed; the values for DOTA agreed well with those previously published.8 Complete binding (>95%) was achieved at 70 °C for all ligands. Thus, replacement of an acetate group on the DOTA skeleton does not lead to noticeably improved radiolabelling at lower temperatures if compared with the parent DOTA. Monophosphinate ligands were labelled worse than DOTA or DO3AP at lower temperatures.
The influence of solution pH was investigated in the range 2–6 and results are shown in Fig. 7. For radioscandium from both sources, the best labelling was observed at pH 4–5 with some decrease at a higher pH, probably due to the formation of colloidal scandium(III)–hydroxide species, as found in the previous studies.9,10 When the solution pH was reduced to 2, labelling efficiency significantly decreased for all the ligands but more for the phosphorus acid DOTA analogues. It is in agreement with the equilibrium data (see above) as monophosphorus acid DOTA analogs form the out-of-cage complexes with higher abundances than DOTA does. So, the optimal radiolabeling yields were achieved using facile conditions – pH 4, reaction time 30 min, and incubation temperature 70 °C.
Unlike for Ln(III) ions,37–40 labelling with 44Sc was not improved. As discussed above, the formation of metal ion complexes of DOTA-like ligands is a two-step process,41,53i.e. formation of the out-of-cage complex is followed by proton removal from, and metal ion transfer into, the ligand cavity as a rate-determining step. Both steps should be optimized to improve labelling efficiency. Here, the basicity of ring nitrogen atoms is similar in all investigated ligands leading to the similar labelling efficiency. In addition, small Sc(III) ions may not fit well into the cavity of the title ligands. A somewhat better labelling with DO3AP might be connected with the rather hard character of the phosphonate group leading to a good interaction with small and hard Sc(III) ions. The effect of the right combination of cavity size, basicity of ring amines and suitable properties of pendant donor atoms for efficient formation of the out-of-cage complex has been shown for phosphinic acid NOTA analogues. Very small trivalent gallium perfectly fits the small cavity of NOTA-like ligands, hard phosphinates are very selective for hard Ga(III) ions and they also decrease the ring amine basicity. It all leads to a very efficient labelling of these ligands with 68Ga.42
To better prove that 44Sc–DO3AP (as the best ligand in the investigated series) has no uptake on bone, its biodistribution was investigated in healthy rats and the results are shown in Fig. 8 and Table S4.† These data show no specific uptake and rapid clearance through urine. The PET image confirmed this observation. Thus, the 44Sc remains in the chelate in vivo and the 44Sc–DO3AP complex is not adsorbed on bone.
The labelling efficiency of DOTA and its analogues was, for the first time, investigated on radioscandium from two sources, generator- or cyclotron-produced 44Sc. Chelator excess over radioscandium necessary for efficient labelling was higher for the generator 44Sc. The difference might be attributed to various amounts of cold metal impurities in radioscandium from each source as cold metal ions compete with radiometals during radiolabelling.56 The best labelling conditions for DO3AP, DO3APABn and DO3APPrA were the same as for DOTA. The phosphonate ligand, DO3AP, showed somewhat better labelling efficiency at low temperatures and it is a hint for possible future ligand designs. The specific activity after labelling was higher for the cyclotron produced 44m/44Sc (∼10 MBq nmol−1) as compared to that for the generator produced 44Sc (∼2 MBq nmol−1). In vitro stability of the Sc(III) complexes is very high as expected for complexes of macrocyclic ligands. No specific uptake and a rapid urine clearance of 44Sc–DO3AP were observed in healthy rats. Slow formation kinetics remains the main challenge in the design of chelators for scandium and lanthanide radioisotopes.
Footnote |
† Electronic supplementary information (ESI) available: Experimental details on potentiometry, FISRE and NMR measurements, figures with NMR and titration data, FISRE isotherms, experimental details and figures for challenge studies, table of specific activities of labelled ligands. See DOI: 10.1039/c5dt04084a |
This journal is © The Royal Society of Chemistry 2016 |